Relapsed/Refractory Multiple Myeloma
Conditions
Keywords
Open-label, dose-escalation, dose-expansion, ISB 1442, relapsed/refractory multiple myeloma
Brief summary
This study is a first-in-human, Phase 1/2, open label study that will evaluate safety and efficacy of ISB 1442 in relapsed/refractory multiple myeloma (R/R MM).
Detailed description
The study will be conducted in two phases: * Phase 1: Dose escalation in R/R MM * Phase 2: Dose expansions in select R/R MM Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a Recommended Phase 2 Dose (RP2D) is established in Phase 1 for a given indication, Phase 2 will be initiated for that indication. Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.
Interventions
DRUGISB 1442 SC injection escalating doses
Participants will receive escalating SC doses of ISB 1442
DRUGISB 1442 SC injection at RP2D
ISB 1442 SC injection dose regimen at RP2D until participants experience disease progression or unacceptable toxicity, or until any other discontinuation criterion is met
Sponsors
Ichnos Sciences SA
Study design
Allocation
RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Participants will be treated at escalating dose levels in Phase 1 (dose-escalation phase) of the study. Once the safety of ISB 1442 is confirmed and a recommended phase 2 Dose (RP2D) is established in Phase 1, Phase 2 will be initiated for that indication. The Phase 2 design uses the Simon two-stage design with stopping rules for lack of activity, as well as stopping rules for toxicity. Participants will receive ISB 1442, until disease progression, unacceptable toxicity, or any criterion for stopping the study drug or withdrawal from the trial occurs.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients aged 18 years or older. 2. Be willing and able to provide written informed consent and any locally required authorization (eg, Health Insurance Portability and Accountability Act of 1996 \[HIPAA\]) prior to any protocol related procedures, including screening evaluations 3. Phase 1: Patients with pathologically confirmed multiple myeloma (MM) who have progressed on or after standard therapy (relapsed/refractory \[R/R\] patients): 1. Must have received at least 3 prior lines of therapy, including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit. (Note: Patients in Australia may have received any of the therapies including PIs, IMiDs, and anti CD38 therapies either in combination or as a single agent; and must not be candidates for regimens known to provide clinical benefit ). 2. Must have measurable M-protein (serum and/or 24-hr urine, or serum free light chains). 4. Phase 2: Patients with pathologically confirmed MM who have progressed on or after standard therapy (R/R patients) 5. Have a body weight ≥ 40.0 kg at screening. 6. Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 2 or less. 7. Have life expectancy of at least 3 months (from date of informed consent signing). 8. Have adequate organ function, including: 1. Aspartate aminotransferase (AST, GOT) and alanine aminotransferase (ALT, GPT) ≤3.0 × ULN; bilirubin ≤1.5 × ULN. Patients with Gilbert's syndrome may have a bilirubin level \>1.5 × ULN, per discussion between the Investigator and medical monitor. 2. Estimated creatinine clearance ≥45 mL/min as calculated using the Cockcroft-Gault formula or 24-hour urine collection. 9. Left ventricular ejection fraction (LVEF) ≥45% as assessed by echocardiogram (ECHO) or multiple gated acquisition (MUGA) scan.
Exclusion criteria
1. Participants with relapsed disease where relapse is characterized only by minimal residual disease parameters (i.e., minimal residual disease positive). 2. Participants with MM with disease where the only measurable parameter is plasmacytoma. 3. Received treatment with anti-CD38 antibodies or CD47 targeted therapies within 1 month of C1D1; systemic anticancer treatments within 14 days before the first dose of study drug (C1D1) or any investigational products within 5 half-lives of C1D1, whichever is appropriate to last therapy received. (eg, non-IMP IMiD, proteasome inhibitor could be considered to be eligible if there is at least 14 days after last dose before C1D1. Note: Treatment with a single course of glucocorticoids is allowed (maximum dose of corticosteroids should not exceed the equivalent of 160 mg \[for example, 40 mg/d for 4 days\] of dexamethasone). Hormonal therapy for prostate cancer or breast cancer (as adjuvant treatment), and treatment with bisphosphonates and receptor activator of nuclear factor kappa-Β ligand inhibitors are allowed. 4. Received autologous stem cell transplantation within 12 weeks of C1D1. 5. Current participation in another interventional study, including other clinical trials with investigational agents (including investigational vaccines or investigational medical device for disease under study) within 4 weeks of C1D1 and throughout the duration of this trial. 6. Prior radiation therapy within 14 days of C1D1; or prior irradiation to \> 25% of the bone marrow. Note: Prophylactic localized (spot) radiation for areas of pain is allowed. 7. Active malignant central nervous system involvement 8. Known to be refractory to platelet or RBC transfusions 9. Known severe allergic or anaphylactic reactions to human recombinant proteins or excipients used in the ISB 1442 formulation. 10. QTc interval \> 480 msec at screening using Fredericia's QT correction formula.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Phase 1: Number of Dose-Limiting Toxicities (DLTS) During the First 28 Days After the First Administration of ISB 1442 (Cycle 1) | Up to 28 days |
| Phase 1: Frequency and Severity Of Treatment-Emergent Adverse Events (TEAEs) | Up to 18 months |
| Phase 2: Multiple Myeloma: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG) | 18 months |
Secondary
| Measure | Time frame |
|---|---|
| Area Under the Concentration Time Curve in Dosing Intervals (AUC0-tau) of ISB1442 in Serum | Up to 28 days |
| Percent Incidence of Anti-Drug Antibody (ADA) and Neutralizing Antibody (nAb) From Baseline Until End-of-Treatment (EOT) | Baseline to 18 months |
| Phase 1 and Phase 2: Time to Progression (TTP) | 18 Months |
| Phase 1 and Phase 2: Time to Next Treatment (TTNT) | 18 Months |
| Phase 1 and Phase 2: Time to Response (TTR) | 18 Months |
| Maximum Concentration (Cmax) of ISB 1442 in Serum | Up to 28 days |
| Phase 1 and Phase 2: Overall survival (OS) | 18 Months |
| Phase 1: Overall Response Rate (ORR) Based on International Myeloma Working Group (IMWG) | 18 months |
| Phase 1 and Phase 2: Complete Response Rate (CRR) Based on International Myeloma Working Group (IMWG) | 18 months |
| Phase 1 and Phase 2: Duration of Response (DOR) Based on International Myeloma Working Group (IMWG) | 18 months |
| Phase 2: Frequency and Severity of Treatment Emergent Adverse Events (TEAEs) | 18 months |
| Phase 1 and Phase 2: Progression free survival (PFS) | 18 Months |
| Time to Reach Maximum Concentration (Tmax) of ISB 1442 in Serum | Up to 28 days |
| Area Under the Concentration Time Curve From Zero to Time t (AUC0-t) of ISB 1442 in Serum | Up to 28 days |
Countries
Australia, India, United States
Outcome results
None listed